Advertisement

Vasculitis Associated with Infection, Malignant Tumors, Drugs, and Other Factors

  • Yeon Joo Jeong
  • Man Pyo Chung
  • Kyung Soo Lee
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Infections are responsible for different types of vasculitis and several mechanisms are involved. However, a causal relationship has only been established in a few instances (polyarteritis nodosa and hepatitis B virus, cryoglobulinemia, and hepatitis C virus). Vasculitides associated with malignancy are infrequent and they are more common in hematologic malignancies such as myelodysplastic syndrome and lymphomas. No statistically significant association has been established between a given vasculitis and a type of malignancy. A large number of drugs can induce vasculitis, the most often implicated drug being propylthiouracil. Imaging studies usually depict the findings of diffuse alveolar hemorrhage in propylthiouracil-induced antineutrophil cytoplasmic antibody associated pulmonary vasculitis.

Keywords

Kawasaki Disease Giant Cell Arteritis Takayasu Arteritis Diffuse Alveolar Hemorrhage Central Nervous System Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aggarwal A, Chag M, Sinha N, Naik S (1996) Takayasu’s arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol 55:49–55PubMedCrossRefGoogle Scholar
  2. Aloush V, Litinsky I, Caspi D, Elkayam O (2006) Propylthioruracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum 36:4–9PubMedCrossRefGoogle Scholar
  3. Belizna CC, Hamidou MA, Levesque H et al (2009) Infection and vasculitis. Rheumatology 48:475–482PubMedCrossRefGoogle Scholar
  4. Bhullar N, Folzenlogen DD (2002) Henoch-Schonlein purpura: upper respiratory tract infection or drug induced? Arch Intern Med 162:222–223PubMedCrossRefGoogle Scholar
  5. Blanchard JN, Powell HC, Freeman WR et al (2003) Recurrent Kawasaki disease-like syndrome in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 36:105–111PubMedCrossRefGoogle Scholar
  6. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M (1998) Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Blatimore) 77:403–418Google Scholar
  7. Brannagan TH III (1997) Retroviral-associated vasculitis of the nervous system. Neurol Clin 15:927–944PubMedCrossRefGoogle Scholar
  8. Brons RH, Bakker HI, Van Wijk RT et al (2000) Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener’s granulomatosis? Clin Exp Immunol 119:566–573PubMedCrossRefGoogle Scholar
  9. Brown KK (2006) Pulmonary vasculitis. Proc Am Thorac Soc 3:48–57PubMedCrossRefGoogle Scholar
  10. Cacoub P, Delluc A, Saadoun D et al (2008) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: Where do we stand? Ann Rheum Dis 67:283–287PubMedCrossRefGoogle Scholar
  11. Cacoub P, Saadoun D (2008) Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 35:30–39PubMedCrossRefGoogle Scholar
  12. Choi HK, Merkel PA, Walker AM, Niles JL (2000) Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43:405–413PubMedCrossRefGoogle Scholar
  13. Chung MP, Yi CA, Lee HY et al (2010) Imaging of pulmonary vasculitis. Radiology 255:322–441PubMedCrossRefGoogle Scholar
  14. DeRemee RA, McDonald TJ, Weiland LH (1985) Wegener’s granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 60:27–32PubMedGoogle Scholar
  15. Dolman KM, Gans RO, Vervaat TJ et al (1993) Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342:651–652PubMedCrossRefGoogle Scholar
  16. Fain O, Guillevin L, Kaplan G et al (1991) Vasculitis and neoplasms. 14 cases. Ann Med Interne 142:486–504Google Scholar
  17. Fain O, Hamidou M, Cacoub P et al (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57:1473–1480PubMedCrossRefGoogle Scholar
  18. Finkel TH, Torok TJ, Ferguson PJ et al (1994) Chronic parvovirus B19 infection and systemic necrotizing vasuclitis: opportunistic infection or aetiological agent? Lancet 343:1255–1258PubMedCrossRefGoogle Scholar
  19. Font C, Miro O, Pedrol E et al (1996) Polyarteritis nodosa in human immunodeficiency virus infection: report of four cases and review of the literature. Br J Rheumatol 35:796–799PubMedCrossRefGoogle Scholar
  20. Fortin PR (1996) Vasculitides associated with malignancy. Curr Opin Rheumatol 8:30–33PubMedCrossRefGoogle Scholar
  21. Garcia-Garcia JA, Macias J, Castellanos V et al (2003) Necrotizing granulomatous vasculitis in advanced HIV infection. J Infect 47:333–335PubMedCrossRefGoogle Scholar
  22. Garcia-Porrua C, Gonzalez-Gay MA (1998) Cutaneous vasuclitis as a paraneoplastic syndrome in adults. Arthritis Rheum 41:1133–1135PubMedCrossRefGoogle Scholar
  23. Gao Y, Zhao MH (2009) Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol 14:33–41CrossRefGoogle Scholar
  24. Gayraud M, Guillevin L, le Toumelin P et al (2001) French Vasculitis Study Group. Long-term follow up of polyarteritis nodosa, microscopic polyarteritis, and Churg–Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675PubMedCrossRefGoogle Scholar
  25. Gherardi R, Belec L, Mhiri C et al (1993) The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum 36:1164–1174PubMedCrossRefGoogle Scholar
  26. Gisselbrecht M, Cohen P, Lortholary O et al (1997) HIV-related vasculitis: clinical presentation and therapeutic approach on six patients. AIDS 11:121–123PubMedGoogle Scholar
  27. Gocke DJ, Hsu K, Morgan C et al (1970) Association between polyarteritis nodosa and Australia antigen. Lancet 2:1149–1153PubMedCrossRefGoogle Scholar
  28. Gordon LK, Goldman M, Sandusky H et al (2004) Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol 111:286–296PubMedCrossRefGoogle Scholar
  29. Greer JM, Longley S, Edwards NL et al. (1988) Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine 67:220–230Google Scholar
  30. Gross WL, Trabandt A, Reinhold-Keller E (2000) Diagnosis and evaluation of vasculitis. Rheumatology 39:245–252PubMedCrossRefGoogle Scholar
  31. Guillevin L, Cohen P, Mahr A et al (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49:93–100PubMedCrossRefGoogle Scholar
  32. Guillevin L, Lhote F, Jarrousse B, Fain O (1992) Treatment of polyarteritis nodosa and Churg–Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne 143:405–416Google Scholar
  33. Guillevin L, Lhote F, Leon A et al (1993) Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 20:289–298PubMedGoogle Scholar
  34. Guillevin L, Mahr A, Cohen P et al (2004) Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 51:482PubMedCrossRefGoogle Scholar
  35. Guillevin L (2004) Virus-induced systemic vasculitides: new therapeutic approaches. Clin Dev Immunol 11:227–231PubMedCrossRefGoogle Scholar
  36. Guillevin L (2008) Vasculitides in the context of HIV infection. AIDS 22:S27–S33PubMedCrossRefGoogle Scholar
  37. Han D et al (2003) Thrombotic and nonthrombotic pulmonary arterial embolism: spectrum of imaging findings. Radiographics 23:1521–1539PubMedCrossRefGoogle Scholar
  38. Hutson TE, Hoffman GS (2000) Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res 13:417–423PubMedCrossRefGoogle Scholar
  39. Javed MA, Sheppard MN, Pepper J (2006) Aortic root dilatation secondary to giant cell aortitis in a human immunodeficiency virus-positive patient. Eur J Cardiothorac Surg 30:400–401PubMedCrossRefGoogle Scholar
  40. Johnson RM, Little JR, Storch GA (2001) Kawasaki-like syndromes associated with human immunodeficiency virus infection. Clin Infect Dis 32:1628–1634PubMedCrossRefGoogle Scholar
  41. Kumar K, Holden WE (1986) Drug-induced pulmonary vascular disease: mechanisms and clinical patterns. West J Med 145:343–349PubMedGoogle Scholar
  42. Lee DH, Huang HP (2004) Kawasaki disease associated with chickenpox: report of two sibling cases. Acta Paediatr Taiwan 45:94–96PubMedGoogle Scholar
  43. Lee KS, Kim TS, Han J et al (1999) Diffuse micronodular lung disease: HRCT and pathologic findings. J Comput Assist Tomogr 23:99–106PubMedCrossRefGoogle Scholar
  44. Manders SM (1998) Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 39:383–398PubMedCrossRefGoogle Scholar
  45. Millikan LE, Flynn TC (1999) Infectious etiologies of cutaneous vasculitis. Clin Dermatol 17:509–514PubMedCrossRefGoogle Scholar
  46. Misiani R, Bellavita P, Fenili D et al. (1992) Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573–577Google Scholar
  47. Naschitz JE, Kovaleva J, Shaviv N et al (2003) Vascular disorders preceding diagnosis of cancer: distinguishing the causal relationship based on Bradford–Hill guidelines. Angiology 54:11–17PubMedCrossRefGoogle Scholar
  48. Pagnoux C, Cohen P, Guillevin L (2006) Vasculitides secondary to infections. Clin Exp Rheumatol 24:S71–S81PubMedGoogle Scholar
  49. Papadogiannakis N, Tolfvenstam T, Fischler B et al (2002) Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant. Clin Infect Dis 35:1027–1031PubMedCrossRefGoogle Scholar
  50. Popa ER, Tervaert JW (2003) The relation between Staphylococcus aureus and Wegener’s granulomatosis: current knowledge and future directions. Intern Med 42:771–780PubMedCrossRefGoogle Scholar
  51. Parker CW (1975) Drug allergy. N Engl J Med 292:511–514PubMedCrossRefGoogle Scholar
  52. Quiceno GA, Cush JJ (2007) Iatrogenic rheumatic syndromes in the elderly. Rheum Dis Clin North Am 33:123–124PubMedCrossRefGoogle Scholar
  53. Rodriguez-Pla A, Stone JH (2006) Vasculitis and systemic infections. Curr Opin Rheumatol 18:39–47PubMedCrossRefGoogle Scholar
  54. Saadoun D, Resche-Rigon M, Thibault V et al (2006) Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 54:3696–3706PubMedCrossRefGoogle Scholar
  55. Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A et al (1990) Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol 17:1458–1462PubMedGoogle Scholar
  56. Solans-Laque R, Bosch-Gil JA, Perez-Bocanegra M et al (2008) Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 35:294–304PubMedGoogle Scholar
  57. Stegeman CA, Tervaert JW, Sluiter WJ et al (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–17PubMedGoogle Scholar
  58. Tervaert JW, Popa ER, Bos NA (1999) The role of superantigens in vasculitis. Curr Opin Rheumatol 11:24–33Google Scholar
  59. Trepo C, Guillevin L (2001) Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 16:269–274PubMedCrossRefGoogle Scholar
  60. Witort-Serraglini E, Del Rosso M, Lotti TM, Matucci-Cerinic M (1999) Endothelial injury in vasculitides. Clin Dermatol 17:587–590PubMedCrossRefGoogle Scholar
  61. Wagner AD, Gerard HC, Fresemann T et al (2000) Detection of Chlamydia pneumonia in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum; 43:1543–1551PubMedCrossRefGoogle Scholar
  62. Wiik A (2005) Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 7:191–192PubMedCrossRefGoogle Scholar
  63. Wiik A (2008) Drug-induced vasculitis. Curr Opin Rheumatol 20:35–39PubMedCrossRefGoogle Scholar
  64. Yanagilhori H, Oyama N, Nakamura K et al (2006) Role of IL-12B promoter polymorphism in Adamantiades-Behcet’s disease susceptibility: an involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J Invest Dermatol 126:1534–1540CrossRefGoogle Scholar
  65. Zhao MH, Chen M, Gao Y, Wang HY (2006) Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 69:1477–1481PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  • Yeon Joo Jeong
    • 1
  • Man Pyo Chung
    • 2
  • Kyung Soo Lee
    • 3
  1. 1.Department of Diagnostic Radiology, Pusan National University HospitalPusan National University School of MedicinePusanKorea
  2. 2.Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Department of Radiology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea

Personalised recommendations